Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $8.65, but opened at $8.00. Oxford BioMedica shares last traded at $8.00, with a volume of 100 shares trading hands.
Analysts Set New Price Targets
Separately, Zacks Research raised Oxford BioMedica to a “hold” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold”.
Get Our Latest Report on OXBDF
Oxford BioMedica Price Performance
Oxford BioMedica Company Profile
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
See Also
- Five stocks we like better than Oxford BioMedica
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
